Oncolytics Biotech (ONCY) +35.3% premarket after announcing positive results from a mid-stage...

|By:, SA News Editor

Oncolytics Biotech (ONCY) +35.3% premarket after announcing positive results from a mid-stage clinical trial examining the use of its lead product candidate Reolysin in helping shrink tumors. ONCY says 95% of patients with squamous cell carcinoma of the lung using Reolysin intravenously in combination with carboplatin and paclitaxel exhibited overall tumor shrinkage.